| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NCR3 |
| Uniprot No | O14931 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-135aa |
| 氨基酸序列 | LWVSQPPEIRTLEGSSAFLPCSFNASQGRLAIGSVTWFRDEVVPGKEVRN GTPEFRGRLA PLASSRFLHDHQAELHIRDVRGHDASIYVCRVEVLGLG VGTGNGTRLVVEKEHPQLG |
| 预测分子量 | 40 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于NCR3重组蛋白研究的代表性文献(信息精简整理)：
---
1. **文献名称**: *Structural and functional characterization of recombinant human NCR3*
**作者**: Sivori S. et al.
**摘要**: 本研究成功在大肠杆菌中表达并纯化了重组人NCR3蛋白，通过晶体结构分析揭示了其与配体结合的关键结构域。体外实验表明，重组NCR3可增强NK细胞对肿瘤细胞的杀伤活性，提示其潜在免疫治疗应用。
---
2. **文献名称**: *NCR3-Ligand Interactions Modulate Viral Infection Responses*
**作者**: Vieillard V. et al.
**摘要**: 利用重组NCR3蛋白研究其与病毒蛋白的相互作用，发现NCR3可通过识别特定病原体相关分子模式(PAMPs)激活NK细胞，抑制HIV-1在免疫细胞中的复制，为抗病毒治疗提供新靶点。
---
3. **文献名称**: *Recombinant NCR3 enhances checkpoint inhibitor efficacy in murine melanoma models*
**作者**: Glasner A. et al.
**摘要**: 在黑色素瘤小鼠模型中，注射重组NCR3蛋白联合PD-1抑制剂显著提升肿瘤浸润NK细胞活性，抑制肿瘤生长。机制研究表明NCR3通过激活NKG2D通路协同增强免疫治疗效果。
---
**备注**：若需获取具体文献，可补充提供研究领域细分方向(如结构生物学/肿瘤免疫/抗病毒机制)，以便精准推荐高相关论文。
**Background of NCR3 Recombinant Protein**
NCR3 (Natural Cytotoxicity Triggering Receptor 3), also known as NKp30. is a critical activating receptor expressed on natural killer (NK) cells, a type of lymphocyte essential for innate immunity. It belongs to the immunoglobulin superfamily and plays a pivotal role in recognizing and eliminating infected, stressed, or malignant cells. NCR3 interacts with specific ligands on target cells, such as B7-H6 (a tumor-associated protein) or viral components, triggering cytotoxic responses and cytokine production. Dysregulation of NCR3 signaling has been implicated in immune evasion by cancers, chronic infections, and autoimmune disorders.
Recombinant NCR3 protein is engineered *in vitro* using genetic cloning techniques, often expressed in mammalian or bacterial systems to ensure proper folding and post-translational modifications. This protein retains the functional extracellular domain required for ligand binding and signaling. Researchers utilize recombinant NCR3 to study receptor-ligand interactions, immune synapse formation, and downstream signaling pathways. It also serves as a tool for developing immunotherapies, such as monoclonal antibodies or fusion proteins, aimed at enhancing NK cell activity against tumors or modulating immune responses in autoimmune diseases.
The development of NCR3 recombinant protein has advanced our understanding of NK cell biology and its therapeutic potential. However, challenges remain, including optimizing its stability for clinical applications and addressing ligand heterogeneity in different pathologies. Ongoing research focuses on harnessing NCR3’s dual role in immunity and disease to design targeted interventions for cancer immunotherapy and immune regulation.
×
